Celsion Net Income 2006-2021 | CLSN

Celsion net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Celsion Annual Net Income
(Millions of US $)
2020 $-21
2019 $-17
2018 $-12
2017 $-21
2016 $-22
2015 $-22
2014 $-25
2013 $-13
2012 $-27
2011 $-23
2010 $-19
2009 $-15
2008 $-12
2007 $35
2006 $-8
2005 $-9
Celsion Quarterly Net Income
(Millions of US $)
2021-09-30 $-5
2021-06-30 $-5
2021-03-31 $-6
2020-12-31 $-3
2020-09-30 $-8
2020-06-30 $-5
2020-03-31 $-5
2019-12-31 $-3
2019-09-30 $-5
2019-06-30 $-6
2019-03-31 $-2
2018-12-31 $5
2018-09-30 $-5
2018-06-30 $-8
2018-03-31 $-4
2017-12-31 $-5
2017-09-30 $-6
2017-06-30 $-5
2017-03-31 $-5
2016-12-31 $-5
2016-09-30 $-6
2016-06-30 $-5
2016-03-31 $-6
2015-12-31 $-6
2015-09-30 $-4
2015-06-30 $-6
2015-03-31 $-7
2014-12-31 $-6
2014-09-30 $-7
2014-06-30 $-7
2014-03-31 $-5
2013-12-31 $-4
2013-09-30 $-4
2013-06-30 $0
2013-03-31 $-5
2012-12-31 $-8
2012-09-30 $-6
2012-06-30 $-6
2012-03-31 $-6
2011-12-31 $-6
2011-09-30 $-6
2011-06-30 $-7
2011-03-31 $-4
2010-12-31 $-5
2010-09-30 $-5
2010-06-30 $-3
2010-03-31 $-6
2009-12-31 $-2
2009-09-30 $-5
2009-06-30 $-5
2009-03-31 $-4
2008-12-31 $-1
2008-09-30 $-4
2008-06-30 $-2
2008-03-31 $-4
2007-12-31 $-3
2007-09-30 $-4
2007-06-30 $44
2007-03-31 $-2
2006-12-31 $-1
2006-09-30 $-1
2006-06-30 $-4
2006-03-31 $-2
2005-12-31 $-2
2005-09-30 $-2
2005-06-30 $-2
2005-03-31 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.040B $0.001B
Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69